NOVAVAX to Present at the Immunotherapeutics and Vaccine (IMVAC) Summit
ROCKVILLE, Md., Aug. 17 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the company will be presenting at the IMVAC Summit. The Conference will take place August 17-19, 2010 at the Royal Sonesta Hotel, Cambridge, MA. Dr. Steven Pincus will be presenting, "Influenza Virus-Like Particle Vaccine Produced in Insect Cells Elicits Hemagglutination and Neuraminidase Inhibiting Antibodies in Immunized Health Adults," on Tuesday, August 17, 2010, and Dr. Ramadevi Raghunandan, Senior Scientist, Immunology will be presenting, "Evaluation of the Safety and Efficacy of a Novel RSV F Particle Vaccine in the Cotton Rat," on Thursday, August 19, 2010.
About Vaccine Forum Washington 2010
ImVacS brings together international vaccine leaders to discuss challenges and current breakthroughs in the world of vaccines. The four vaccine-focused meetings address innovating strategies to meet current health threats, changing technology for vaccine manufacture, top challenges faced during pre-clinical development, and progress underway for adjuvants and novel delivery systems. Altogether, ImVacS provides a snapshot of where vaccine development stands today. For more information, please see www.ImVacs.com.
Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.
SOURCE Novavax, Inc.